2017 Annual Meeting AANextra—Sunday, April 23

THE ANNUAL MEETING NEWS DAILY

Sunday, April 23, 2017

This Morning’s Presidential Plenary Session to Showcase Most Significant Findings in Neurology

Inside

Hall Kicks Off Today 10 Exhibit with Opening Luncheon the Neurology Career 11 Visit Center at Two Locations Session I Opens 12 Poster This Morning at 8:30, Posters Grouped by Topic “Neighborhoods”

Beginning at 9:15 this morning in Exhibit Hall A, the AAN’s premier lecture awards for clinically relevant research are set to take center stage when leading researchers will speak on the most significant findings in neurology.

and Publications 24 Education Station Experiential Learning Area

Continued on page 35 u

Brain Health Fair Educates Boston Area Residents

Today’s New Neuroscience in the Clinic Sessions Highlight MS and Disorders of Language and Action The New Neuroscience in the Clinic Sessions will feature a mix of scientists and clinicians engaged in lively case discussions to integrate scientific research with clinical application. A moderator will introduce and provide background on a case and invited speakers will frame the case in scientific and clinical context. Thematic abstract presentations will provide additional framework. The session will conclude with a panel discussion.

Check out today’s sessions and look for more throughout the week.

The chance to hold a human brain, learn from expert neurologists, and hear Maria Shriver discuss her initiative to raise money for women-based research into Alzheimer’s disease drew more than 1,500 Boston area neurology patients, caregivers, families, and students to the Brain Health Fair at the Boston Convention and Exhibition Center on Friday, Continued on page 14 u

Neuroscience in the Clinic: Neurobiology and Treatment of Disorders of Language and Action 1:00 p.m.–3:00 p.m. Coordinator: H. Branch Coslett, MD, FAAN

Continued on page 9 u

Sunday, April 23, 2017 • AANextra

1

HARNESSING SCIENCE

to improve lives

At MT Pharma America, we understand that people with debilitating neurological diseases are determined to live life on their own terms. This is especially true for people living with amyotrophic lateral sclerosis, or ALS, our current focus.

That is why we have paired a global expertise in research and development with veterans in the US life sciences industry. We are working together with advocacy organizations to expand disease education and elevate awareness that may lead to improvements in diagnosis, treatment, and discovery.

Discover our current efforts at Booth 721

and mt-pharma-america.com

Inspired by patients. Grounded in science.

Š 2017 MT Pharma America, Inc. All rights reserved. CP-MTPA-US-0002 04/17

Sunday, April 23 1 1 1 5 5 6

This Morning’s Presidential Plenary Session to Showcase Most Significant Findings in Neurology Brain Health Fair Educates Boston Area Residents Today’s New Neuroscience in the Clinic Sessions Highlight MS and Disorders of Language and Action Help Prepare Boston Public School Youth for Health and Science Careers New to the Annual Meeting? These Orientation Sessions Are for You! Applications Open for Unique AAN Leadership Program Opportunities

16 Members Elect New Board, Approve

The Vision of the AAN is to be indispensable to our members.

24 Education and Publications Station

The Mission of the AAN is to promote the highest quality patient-centered neurologic care and enhance member career satisfaction.

Bylaws Amendment

Experiential Learning Area

25 Get the Most Out of Your Week: Download the Annual Meeting Mobile App!

25 Boxed Lunch Menu Sunday, April 23

25 Learn About the Axon Registry at the Annual Meeting 26 Tweets of the Day 29 Luncheon Brings Together Past, Present, and Future Presidents

Contact Information: American Academy of Neurology 201 Chicago Avenue Minneapolis, MN 55415 USA

(800) 879-1960 (Toll Free) or (612) 928-6100 (International) (612) 454-2744 memberservices@aan.com AAN.com

Phone:

Fax: Email: Website:

AAN Executive Director/CEO:

Catherine M. Rydell, CAE

Managing Editor: Angela Babb, CAE

7 Choosing the Right Practice Setting 10 Exhibit Hall Kicks Off Today with

30 Daily Reminders

32 Complete Neurology Survey to Get

Writers: Ryan Knoke, Sarah Parsons

11 Check Out Today’s Experiential

33 Where Is the AAN Store?

37 What Are People Saying?

38 Meet the Neurology Resident

Photography: Siu Lee

Opening Luncheon

Learning Area Highlights

11 Visit the Neurology Career Center at Two Locations

This Free ‘Essential Tool’

& Fellow Section Editors and Team Members

12 Poster Session I Opens This

Morning at 8:30, Posters Grouped by Topic “Neighborhoods”

12 Visit the UCNS Booth at the Annual Meeting

Editor: Tim Streeter Designer: Jim Hopwood Printing: Universal Wilde, Inc. Email: aannews@aan.com AANextra is published by the American Academy of Neurology.

The American Academy of Neurology’s registered trademarks and service marks are registered in the United States and various other countries around the world. “American Brain Foundation” is a registered service mark of the American Brain Foundation and is registered in the United States.

Today’s AAN Section Meetings Sunday, April 23—Westin Galleria 12:00 p.m.–1:00 p.m.

Autoimmune Neurology Section Epilepsy Section Geriatric Neurology Section Neurohospitalist Section Neurohealth & Integrative Neurology Section

4

Sunday, April 23, 2017 • AANextra

, AprIL SUNDAY

to ary Session y idential Plen ings in Neurolog Find ing’s Pres This Morn Most Significant Showcase

THE ANNUAL

MEETING

NEWS

DAILY

Inside

t Hall Kicks

23, 2017

Off Today

eon ng Lunch 10 Exhibi with Openi

11

r

Caree Neurology Visit the Two Locations at Center I Opens Session

ng at 8:30, 12 Poster This Morni ed by

5:00 p.m.–6:00 p.m.

Business Administration Section Movement Disorders Section Neurogenetics Section Stroke & Vascular Neurology Section

Group ods” Posters Neighborho Topic “ tion and

Publications

24 Educa Experiential Station a r lecture premie leading the AAN’s stage when Hall A, center g in Exhibit set to take in neurology. page 35 u s h are ed on this mornin finding Continu ing at 9:15 ly relevant researc significant Beginn most for clinical on the speak awards hers will researc

ates lth Fair Educ Brain Hearea Residents Boston A

Learning Are

e in Neuroscienclight High Today’s New Sessions the Clinic isorders of Language MS and Don and Acti

s will Session d in engage in the Clinic h cience and clinicians c researc Neuros ts The New mix of scientis integrate scientifiintroduce a tor will ions to feature discuss A modera invited lively case application. on a case and and c with clinical background in scientifi ations the case t present and provide tic abstrac The session rs will frame speake . Thema ork. context al framew ion. clinical addition discuss will provide e with a panel s and will conclud session out today’s out the Check more through and look for

iology

Neurob and Action week. ge in the Clinic: , of Langua cience Coslett Neuros of Disorders gists, Branch neurolo ator: H. u Treatment 9 from expertmoney for Coordin ed on page 00 p.m. than brain, learn to raise Continu 1:00 p.m.–3: a human her initiative drew moreand to hold extra discuss er’s disease families, • AAN MD, FAAN The chance 2017 Maria Shriver h into Alzheim , caregivers, tion and April 23, and hear researc Sunday, gy patients Boston Conven u -based 14 women area neurolo Fair at the ed on page Continu Brain Health 1,500 Boston s to the student Center on Friday, on Exhibiti

1

The American Academy of Neurology sincerely thanks Universal Wilde, Inc. for its exceptional service, steadfast professionalism, and high-quality standards, as well as its generous donation of the 2017 Brain Health Fair program guide.

Help Prepare Boston Public School Youth for Health and Science Careers Make a Donation to AAN Gives Back The AAN is proud to partner with The Center for Community Health and Health Equity at Brigham and Women’s Hospital to help give back to the Boston community this week during the Annual Meeting. Your support will help send Boston Public School ninth graders through the innovative Summer Science Academy program, exposing them to health care professions in a hospital setting, and providing hands-on science education that links to real-world professional—and personal—application.

student funding. The AAN’s goal is to raise $5,000 by the end of the meeting, and the Academy will match up to $2,500 in AAN Gives Back donations.

To learn more and donate, visit AAN.com/ conferences/2017-annual-meeting/aangives-back.

Added Audeh, “We work hard to guide our students toward taking their place in the adult world, hopefully making meaningful contributions in the science field and beyond. The Summer Science Academy’s partnership with the AAN makes that work more tangible, meaningful, and possible.”

“We are so excited to be partnering with the AAN for many reasons, but it is very exciting and powerful to tell our students that the leading scientists and doctors in the field of neurology are supporting them as they continue their science education and think about careers in health science and medicine,” said Pamela Audeh, manager of youth programs at the center. “To give underserved students the support of the science community as they embark on their futures in science sends a strong message that they are important, their future matters, and education is critical.”

Donations will provide transportation, equipment, public health curriculum, and

New to the Annual Meeting? These Orientation Sessions Are for You! Get the most out of your first Annual Meeting experience at one of two Annual Meeting Orientation Sessions taking place this week. These informative and interactive one-hour sessions are designed to highlight a basic overview of the Annual Meeting, including: Programs and events going on throughout the week Information on networking opportunities Valuable AAN resources designed for all member types and career stages How to use the Annual Meeting Mobile App Tips on can’t-miss social and networking events Sunday, April 23 / 8:00 a.m.–9:00 a.m.

Location: HeadTalks Stage Host: Carlayne E. Jackson, MD, FAAN Wednesday, April 26 / 7:00 a.m.–8:00 a.m.

Location: HeadTalks Stage Host: Maisha T. Robinson, MD, MS

Sunday, April 23, 2017 • AANextra

5

Applications Open for Unique AAN Leadership Program Opportunities Today’s challenging health-care environment creates a special need for great leadership, and the AAN is committed to helping members expand their leadership potential.

That’s why we’re looking for members from different practice settings, genders, and ethnicities who are interested in taking their skills to the next level and, in turn, further advancing the profession of neurology and the growing needs of patients.

Jeffrey C. McClean II, MD, FAAN If you’re interested in being part of the next generation of neurology leaders, you are encouraged to apply to one of these prestigious programs.

This program provides customized individual leadership development training, one-on-one coaching, and mentoring opportunities with AAN leadership and member neurologists.

AAN.com/view/TransformingLeaders

Jeffrey C. McClean II, MD, FAAN, vice chair of the Leadership Development Committee, said, “Given the rapidly evolving health care landscape, it is essential that neurologist leaders are positioned and equipped to influence important decisions that impact our field and our patients. The various AAN Leadership Programs each target a particular career stage, member demographic, or type of leadership. From highly selective and intensive 10-month programs to Leadership University courses available to all members at the Annual Meeting, the common thread is development of effective leadership skills often lacking in our medical education.”

Emerging Leaders Program

McClean, who completed the Emerging Leaders Program in 2014, added, “Regardless of whether you intend to lead in a small clinic, large hospital, academic institution, national organization, or government, these programs will provide tools to help you succeed. I truly believe these programs are the most important investment the AAN can make for the future of our field.”

Live Well, Lead Well—A Well-being and Resiliency Program for Neurologists Application Deadline: June 5

A unique nine-month program for US member neurologists designed to reduce and prevent burnout by empowering them to cultivate well-being and resilience in their lives; increase engagement at work; and develop strong, lasting leadership skills. AAN.com/view/livewelleadwell

Application Deadline: June 5

An intensive 10-month program for US female AAN member neurologists 10 or more years out of neurology training who have demonstrated effective leadership skills and an interest in professional development, and who would like to assume roles of responsibility within the AAN and the field of neurology. The program gives participants a forum to address controversial topics in medicine and an opportunity to cultivate essential skills for supervising a team, being supervised, managing patients, and negotiating busy career and personal lives. AAN.com/view/WLN Application Deadline: July 1

A prestigious and interactive six-month program designed to identify, engage, and mentor up to 20 AAN members who are less than 10 years out of residency or training; are committed to professional, community, and society leadership; and are looking to develop and grow their leadership skills and apply them to long-term AAN involvement.

AAN.com/view/EmergingLeaders

Don’t Miss Leadership University Programs—Included with Your Registration!

The popular Leadership University programs have been expanded for 2017. Explore how to become an emerging female leader in your organization or learn how to lead by example in promoting personal well-being and resiliency with these new course offerings from the AAN’s suite of Leadership University courses, which are included with your registration.

Today’s Offerings: Gender Issues in Leadership Sunday, April 23 / 1:00 p.m.–5:00 p.m.

BCEC 204 AB Directors: Barbara L. Hoese, President, Pentecore Coaching; Lyell K. Jones, MD, FAAN; Bert B. Vargas, MD, FAAN; Maisha T. Robinson, MD, MS

Leadership Challenges in Practice

Transforming Leaders Program

Sunday, April 23 / 1:00 p.m.–5:00 p.m.

BCEC 257 AB

An elite 10-month intensive leadership training program for US member neurologists who are 10 or more years out of residency.

Director: James C. Stevens, MD, FAAN

Application Deadline: June 5

6

Women Leading in Neurology

Sunday, April 23, 2017 • AANextra

Choosing the Right Practice Setting When you begin searching for that perfect practice opportunity, you may be surprised at the various practice settings that exist today. There is no “right” or “wrong” practice setting—but it is important to examine the pros and cons of each model and carefully consider the risks and rewards to find the setting that is “right” for you.

First, let’s consider single specialty versus multi-specialty practice. A single-specialty group will be like-minded with fewer competing interests, which enables faster decision-making, especially involving expenditures. With neurology as the sole focus of the practice, call coverage can be split and office staff can be shared, minimizing overhead expenses. Cost sharing is simplified as costs can be equally divided.

Multi-specialty groups offer different advantages. Inherent to this model is a built-in referral base which is extremely beneficial, especially to a new physician trying to build a patient base. There is a collective benefit to the group from referring patients within the group and the built-in ability for primary care and specialty physicians to consult together. Multispecialty groups often develop ancillary services to increase revenue and serve their patients. Large groups are defined widely, from groups of 7-10 physicians to groups exceeding 100 physicians. Large groups allow overhead costs to be divided among more physicians resulting in less financial

risk to any single physician. Larger groups have more leverage when negotiating reimbursement rates with payers, and cash flow is more predictable making ancillary development easier. Clinical synergies and referral opportunities also exist in large groups. However, there are some disadvantages. With more physicians in the group, there is a greater likelihood of clashes in personality or practice style. There may be a hierarchy of senior versus junior physicians or among specialties, both of which can cause difficulty in income distribution decisions. Each physician accepts a reduced role in governance with sacrificed independence, along with liability for group financial and clinical performance.

fewer physicians weighing in. Often, small groups are also single specialty, allowing for focused expertise of administrative staff.

Each physician bears more responsibility for their colleagues’ performance and financial losses are shared. Small groups also have less predictable referrals, along with less capital and patient volume for ancillary investments.

Continued on page 30 u

Small groups are usually defined as 6 or less. As compared to large groups, overhead costs and risks are still shared, but among fewer physicians. There is a greater role in governance and faster decisionmaking due to

MEM: 16 Live Well Ads Ad—Half horizontal Page> AANextra Placed in AANextra 8.25 x 4.4375 +0.125 bleed, 4C

Live Well Taking Care of Your Patients Starts with Taking Care of You

Neurologists have one of the highest rates of burnout and lowest rates of work-life balance among medical specialties.

Find practical solutions to revitalize your well-being.

AAN.com/LiveWell

We’re About to Give You Something No One Else Does.

Coming Soon Be one of the first to know. www.mytreatmentexperience.com/hcp

BAYER and the Bayer Cross are registered trademarks of Bayer. ©2017 Bayer HealthCare Pharmaceuticals Inc. Whippany, NJ 07981.

All rights reserved. PP-721-US-0681 March 2017

Today’s New Neuroscience in the Clinic Sessions Highlight MS and Disorders of Language and Action continued from cover Recent advances in behavioral neurology, neuroimaging, and neurophysiology have substantially updated the understanding of aphasia and disorders of action such as hemiparesis and apraxia. This evolving conceptualization, however, has not been incorporated into the prevailing notions of these disorders and their treatment. The lack of familiarity with current concepts of the neurobiology of language and action is important as it prevents clinicians from evaluating and exploiting current and emerging treatments for these disorders.

To address this issue, this course will focus on recent behavioral, non-invasive brain stimulation (e.g., TMS, tDCS) and neuroimaging investigations of the neurobiology of language and action. Recent advances in the neurobiology of language and action will be presented. These presentations will be followed by talks discussing the potential clinical implications of the evolving understanding of language and action.

1:00 p.m.–1:10 p.m. Introduction and Presentation of a Case H. Branch Coslett, MD, FAAN 1:10 p.m.–1:40 p.m. Neurobiology of Language and Implications for Therapy Peter Turkeltaub, MD, PhD 1:40 p.m.–2:00 p.m. Neurobiology of Higher Level Action and Implications for Therapy H. Branch Coslett, MD, FAAN 2:00 p.m.–2:15 p.m. N1.001: Anatomical Network Degeneration in Primary Progressive Aphasia John Medaglia, PhD 2:15 p.m.–2:30 p.m. N1.002: Characterization of Primary Progressive Aphasia and Prediction of Naming Decline by Multimodality MRI Andreia Faria 2:30 p.m.–3:00 p.m. Panel Discussion

Neuroscience in the Clinic: Child Neurology: Neurologic Disorder Through a Lifespan—A Focus on MS 3:30 p.m.–5:30 p.m.

Coordinators: Shafali Jeste, MD; Rebecca K. Lehman, MD The onset of multiple sclerosis (MS) most commonly occurs in young adults, but onset may also occur in children and in the elderly. Pathological features include both focal demyelination, inflammation, neuronal and axonal loss, as well as a more global loss of central nervous system tissue integrity. Cognitive impairment is a major source of morbidity for patients with MS, but cognitive sequelae vary by age. In this course, we will take a “lifespan” approach to the clinical, neurobiologic, and radiographic aspects of cognitive impairment in MS. This course will provide up-to-date information for all clinicians caring for patients with MS and will foster discourse between pediatric and adult neurologists.

3:30 p.m.–3:35 p.m. Case Report: Pediatric MS Patient Story Outlining Cognitive Changes Maria Pia Amato, PhD 3:35 p.m.–3:40 p.m. Case Report: Elderly Adult MS Patient Story Outlining Changes over Time in Cognition Lauren B. Krupp, MD, FAAN 3:40 p.m.–3:50 p.m. Neuropsychological and MRI Features of Cognitive Impairment in Youth with MS Christine Till, PhD 3:50 p.m.–4:00 p.m. Neuropsychological and MRI Features of Cognitive Impairment in Elderly with MS Lauren B. Krupp, MD, FAAN 4:00 p.m.–4:10 p.m. Management of Cognitive Impairment in Pediatric MS Patients Brenda Banwell, MD, FAAN 4:10 p.m.–4:20 p.m. Management of Cognitive Impairment in Elderly MS Patients Lauren B. Krupp, MD, FAAN 4:20 p.m.–4:35 p.m. N2.001: Risks of Psychiatric Disorders in Children and Young Adults with Demyelinating Diseases of the Central Nervous System: A National Record-linkage Study Julia Pakpoor, MBBS 4:35 p.m.–4:50 p.m. N2.002: Structural Connectivity Abnormalities Underlying Cognitive Impairment in Pediatric Multiple Sclerosis Ermelinda De Meo 4:50 p.m.–5:30 p.m. Panel Discussion: Emerging Studies, Role of Current Therapies, Consideration of NEDA (No Evidence of Disease Activity), and the Concept of Cognitive Rehabilitation

Sunday, April 23, 2017 • AANextra

9

Exhibit Hall Kicks Off Today with Opening Luncheon Be sure to stop by Exhibition Halls B2 & C beginning at 11:30 a.m. today to kick off the Exhibit Hall with an Opening Luncheon, sponsored by Biogen. The Exhibit Hall Opening Luncheon, is an excellent opportunity to socialize with fellow attendees and preview the latest products and services available in the neurologic industry from more than 270 exhibitors.

Exhibitors include pharmaceutical companies; medical device vendors, equipment, and technology companies; and scores of voluntary health associations dedicated to helping people live with neurologic disease. This invaluable convergence provides neurology professionals an expedient way to get up-to-date on the latest and most cutting-edge, patient-focused products, services, and therapies in the field of neurology.

Exhibit Hall Features NEW! Office of the Future Pavilion This new and exciting concept, brought to you by Gold sponsors Outcome Health and Health Monitor Network, will showcase the latest office technologies and encourage participation in group discussions about how peers have been able to implement successfully and efficiently new and emerging technologies in practice. While there, don’t forget to get your complimentary professional headshot, sponsored by SK biopharmaceuticals.

NEW! Special Monday Evening Networking Event If you aren’t able to make it to the opening lunch, this special reception from 4:30 p.m. to 6:00 p.m. is a great way to check out the Exhibit Hall and mingle with exhibitors and poster authors while enjoying hors d’oeuvres and beverages sponsored by Sunovion Pharmaceuticals.

Passport Contest Visit participating booths to get your Exhibit Hall “passport” stamped, then drop it off at the premier passport booth, designated at the top of each day’s passport, to be entered into a drawing for exciting prizes, including Amazon Echos, Sonos Play Smart speaker, Bose noise cancelling headphones, $500 Amazon gift cards, a free one-year AAN membership, 2017 Fall Conference registration, and 2018 Annual Meeting registration. A special Grand Prize winner of the Passport Contest will be drawn at 2:45 p.m. on Wednesday, April 26, and you must be present to win.

Complimentary Lunches and Coffee Breaks Registered attendees can enjoy complimentary lunches or relax for coffee breaks. Lunch is available Sunday through Wednesday from 11:30 a.m.–1:00 p.m. and coffee breaks are available Sunday, Monday, and Tuesday from 3:00 p.m.– 3:30 p.m. in the Exhibit Hall. Sunday’s coffee break is sponsored by Supernus Pharmaceuticals Inc. Technology Pavilion See technology on the front line of improving patient care and speak with vendors about how you can use those products to improve patient care or streamline your office process.

First-time Exhibitors Area Welcome more than 50 exhibitors appearing at the AAN Annual Meeting for the first time, displaying new therapies, technologies, and services targeted for neurology needs.

Association Neighborhood This area contains exhibitors from nonprofit scientific organizations, including many you have heard of—and some that are probably new to you!

Career Fair Visit 28 organizations that are recruiting and offering career resources. If you are actively looking for a career change, want to create or update your profile and post your CV, or seek career guidance from a mentor, visit the AAN’s Career Center, its neighbors in the Career Fair, and additional recruiters throughout the Exhibit Hall.

Publishers Row With massive advances in neurologic research and patient care, publishers are offering a wider array of publications. Visit Publishers’ Row to learn what’s new on the bookshelves and in the cloud!

Exhibit Hall Hours Sunday, April 23

11:30 a.m.–4:00 p.m.

New! Opening Lunch Reception 11:30 a.m.–1:30 p.m.

Monday, April 24

11:30 p.m.–4:30 p.m.

New! Exhibit Hall

Networking Reception 4:30 p.m.–6:00 p.m.

Tuesday, April 25

11:30 a.m.–4:00 p.m.

Wednesday, April 26 11:30 a.m.–3:00 p.m.

Check Out Today’s Experiential Learning Area Highlights Get ready to experience interactive, new ways of exploring, engaging, and learning at today’s Experiential Learning Areas.

Each area will offer a variety of real-world experiences designed to engage you intellectually, emotionally, and socially while serving up fresh ideas to help you personally and professionally.

Highlights From Member to Leader: How to Engage with the AAN 12:00 p.m.–1:00 p.m.

HeadTalks Experiential Learning Area Terrence L. Cascino, MD, FAAN Jeffrey C. McClean II, MD, FAAN Christine Phelps, Deputy Executive Director, AAN Institute Enhanced Well-being Through Mentoring 1:00 p.m.–1:45 p.m.

Live Well Experiential Learning Area Joanne Smikle, PhD

AAN Research Program Day Research Corner Experiential Learning Area 1:30 p.m.–2:00 p.m.

AAN Research Program Alumni Panel Discussion Michael R. Wilson, MD 2:30 p.m.–3:00 p.m.

Nuts and Bolts of the AAN Research Program: Explanations of How Much Funding Is Available and What Kind of Research Is Accepted Aleksandar Videnovic, MD, MSc, FAAN 4:00 p.m.–4:30 p.m.

Writing a Great Research Program Grant Proposal Jeffrey Gelfand, MD, MAS, FAAN

Visit the Neurology Career Center at Two Locations Once again, the AAN’s Neurology Career Center is on-site at the Annual Meeting to help members pursue new job opportunities.

You’ll find the Career Center in the North Lobby of the Boston Convention and Exhibition Center and the Career Fair in the Exhibit Hall.

Find tools and resources to help support your job search, including:

Career Compass Job Guide with hot job openings and job search tips Online Job Fair: Apply for jobs of interest within minutes Articles on popular career topics like networking and interviewing Job seekers also can enjoy a selection of free t-shirts, pens, and flash drives containing insightful articles on acing the job search process (while supplies last).

WIN $500!

Create or update a job seeker profile by April 28, 2017, to be entered into a drawing to win $500 from the Neurology Career Center. See complete Sweepstakes Rules at AAN.com/careers/ career-events.

Sunday, April 23, 2017 • AANextra

11

Visit the UCNS Booth at the Annual Meeting

Brenda Riggott

Did you know the United Council on Neurologic Subspecialties has a new leader? You can meet Executive Director Brenda Riggott at the UCNS booth at the Annual Meeting. Riggott joined UCNS in November after serving as corporate relations and foundation director

for the American Association of Neuromuscular and Electrodiagnostic Medicine in Rochester, MN. If you have questions about UCNS certification or accreditation, Riggott and her staff will be present to share their expertise.

Poster Session I Opens This Morning at 8:30, Posters Grouped by Topic “Neighborhoods”

Remaining Poster Session Schedule Poster Session II

Poster Session IV

Poster Session III

Poster Session V

Monday, April 24: 8:30 a.m.–7:00 p.m. / author standby from 5:30 p.m.–7:00 p.m.

Tuesday, April 25: 8:30 a.m.–7:00 p.m. / author standby from 5:30 p.m.–7:00 p.m.

12

Sunday, April 23, 2017 • AANextra

111 112 113 114

If you can’t get enough cutting-edge science, join today’s lunchtime Poster Discussion Session at the poster discussion stage between 11:45 a.m. and 12:45 p.m., where a group of 10 abstracts will be presented by their authors in a five-minute data blitz with a moderator leading stimulating discussion on the content.

118 117 116 115

Be sure and check out today’s interactive, touchscreen ePosters at the virtual hall kiosk for another great opportunity to further explore scientific posters.

Movement Disorders Lunchtime Poster Discussion Session

119 120 121 122 123 124

Movement Disorders ePoster Session

E

130 129 128 127 126 125

99 92 89 86 83 82

98 97 96 93 94 95 88 87

C D

100 91 90 85 84 81

Group A: Movement Disorders Group B: Research Methodology and Education; Practice, Policy, and Ethics; Movement Disorders ePosters Group C: Aging and Dementia Group D: Movement Disorders Poster Discussion Group E: Neuromuscular and Clinical Neurophysiology (EMG) Group F: General Neurology; Neuro-oncology; Headache; Pain and Palliative Care Group G: Epilepsy/Clinical Neurophysiology (EEG) Group H: Cerebrovascular Disease and Interventional Neurology; Infectious Disease Group I: MS and CNS Inflammatory Disease

G F

131 132 133 134 135 136 137

New this year, we’ve clustered all topic-related posters together into “neighborhoods” to enhance your discussions and make the posters easier to navigate. Neighborhoods include:

161 148 223 240 160 162 241 250 147 149 159 163 224 239 150 146 242 249 164 158 225 238 178 145 151 157 165 243 248 152 179 226 237 156 166 176177180 244 247 155 167 175 181 227 236 245 246 154 168 193 228 235 182 153 169 173174183 192 194 229 234 170 191 195 172 184 196 230 233 190 171 185 206 189 197 231 232 207 186 205 188 198 208 108107 204 199 106 187 203 209 217 109 200 202 210 216 218 110 201 211 215 219 212 214 220 251 213 221 256 252 222 253 257 255 105 254 258 104 266 267 265 259260 103 102 282 268 264263 261 269 101 283 281 270 262 284 280 302 271 279 76 285 63 43 77 75 303 301300 286 278 272 62 64 42 74 277 273 44 78 328 304 65 61 299 287 41 276 274 45 79 73 305 327 60 288 66 46 40 80 72 326 306 298297 289 275 59 71 47 39 325 307 290 329 48 38 324 308 296295 291 358 330 67 37 309 323 357 331 292 68 58 359 322 310 294293 69 57 49 386 360 356355 332 311 321 56 333 70 385 361 320 312 50 36 55 387 384 362 354353 334 319 313 51 35 412 388 335 383 34 363 318 314 52 352 411 389 382 33 364 317 315 53 410 390 381 365 316 54 32 409 336 391 336 380 31 408 392 351 337 337 16 15 407 393 350 338 338 366 406 339 17 14 379 367 349 339 340 378 368 348 340 18 13 347 341 341 394 377 369 405 346 342 342 4 5 27 26 395 19 12 376 370 404 396 345 343 343 375 63 28 25 20 11 371 403 397 344 374 372 72 29 24 402 398 21 10 401 399 373 81 30 23 22 9 400

4 14 3 14 142 141 0 14 139 138

Today’s Poster Session I will run from 8:30 a.m. to 5:30 p.m. in Exhibit Hall B of the convention center, with presenter standby from 4:00 p.m. to 5:30 p.m.

B

A

Wednesday, April 26: 8:30 a.m.–7:00 p.m. / author standby from 5:30 p.m.–7:00 p.m.

Thursday, April 27: 8:30 a.m.–7:00 p.m. / author standby from 5:30 p.m.–7:00 p.m.

H

I

Poster Session VI

Friday, April 28: 8:30 a.m.–5:30 p.m. / author standby from 4:00 p.m.–5:30 p.m.

TURNING NEUROLOGY RESEARCH INTO RECOVERY — FASTER. At Houston Methodist, we are pioneering research in neurostimulation and neuroregeneration to restore mobility and cognitive function in patients with neurological disorders. In both science and clinical trials, we are broadening our understanding of stroke, Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), brain tumors, epilepsy, and spinal disorders, and getting new technologies and treatments to our patients — faster.

Visit houstonmethodist.org/ni and explore all the ways we’re leading medicine.

Brain Health Fair Educates Boston Area Residents continued from cover

which was proclaimed Brain Health Awareness Day by Boston Mayor Marty Walsh.

Attendees learned about the wonders of the brain, new treatments for brain diseases, and the latest advancements in brain disease research. Important resources—including local and international neurologist experts—were on hand to offer advice and answer questions about a variety of brain diseases including multiple sclerosis, Alzheimer's and dementia, epilepsy, stroke, Parkinson's and movement disorders, pain and headache, concussion, the latest advances in child neurology, and other brain diseases.

The free, family-friendly day featured: “Ask a Neurologist” booth Latest treatments and research advances Prevention and healthy lifestyle tips 20-foot inflatable, interactive walkthrough brain

Free bike helmet pickup Opportunity to hold an actual human brain and view animal brains, including mouse and dolphin Brain-inspired crafts Cranial nerve stations

The 2017 Brain Health Fair Platinum Sponsor was Allergan; Gold Sponsor was Supernus Pharmaceuticals, Inc.; and Silver Sponsors were Sanofi Genyzme, Sunovion Pharmaceuticals Inc., PSAV Presentation Services, Freeman.

For more information on the event, visit BrainHealthFair.com.

Sunday, April 23, 2017 • AANextra

15

Members Elect New Board, Approve Bylaws Amendment Academy members attending yesterday’s AAN 2017 Business Meeting voted to elect the nominees for the 2017–2019 AAN and AAN Institute Boards of Directors. Members also approved a change to the AAN bylaws to improve the description of what responsibilities are fulfilled by the AAN’s executive director and to confirm that the AAN president and treasurer are not “statutory employees” of the AAN. Board Treasurer Lisa M. Shulman, MD, FAAN, and Executive Director Catherine M. Rydell, CAE, reported to members on the robust financial health of the Academy and key successes during 2016.

2017–2019 AAN Board of Directors

President Elect James C. Stevens, MD, FAAN

President Ralph L. Sacco, MD, MS, FAHA, FAAN

James C. Stevens MD, FAAN, has been a private practicing neurologist and specialist in sleep disorders medicine at the Fort Wayne Neurological Center for the past 29 years. He received his medical degree from the Indiana University School of Medicine (IUSM), where he graduated at the top of his class, receiving AOA honors his junior year. He completed his neurology resident training at James C. Stevens, MD, FAAN Indiana University, where he was a multi-year recipient of the Alexander Ross Award for outstanding neurologic research. He currently serves as a professor of neurology for the IUSM.

Ralph L. Sacco, MD, MS, FAHA, FAAN, is the chairman of neurology; Olemberg Family Chair in Neurological Disorders; Miller Professor of Neurology Public Health Sciences, Human Genetics, and Neurosurgery; executive director of the Evelyn McKnight Brain Institute; Senior Associate Dean for Clinical and Translational Science, University of Miami, Miller School of Medicine; Ralph L. Sacco, MD, and chief of the neurology service at MS, FAHA, FAAN Jackson Memorial Hospital. A graduate of Cornell University and a cum laude graduate of Boston University School of Medicine, he also holds a master’s in epidemiology from Columbia University, School of Public Health. Sacco completed his neurology residency training and postdoctoral training in stroke and epidemiology at Columbia Presbyterian in New York. He was previously professor of neurology, chief of Stroke and Critical Care Division, and associate chairman at Columbia University before taking his current position in 2007.

Sacco is an international expert in stroke epidemiology and health disparities. He is the principal investigator of the Northern Manhattan Study, the Florida Puerto Rico Collaboration to Reduce Stroke Disparities, AHA/ASA Bugher Center of Excellence, as well as co-investigator of multiple other NIH grants. Sacco has published extensively with over 600 peer-reviewed articles (h-index 101) in the areas of stroke prevention, treatment, epidemiology, risk factors, vascular cognitive impairment, human genetics, and outcomes.

16

Stevens has been a participant, co-author, and/or principal investigator in over 80 clinical trials dealing with a wide variety of neurologic diseases. He has also been involved with the development, authorship and/or reviewer for over 80 clinical practice guidelines submitted by the AAN. He has held many leadership positions within the Academy, serving as the chair of the Practice Committee, member of the Quality Standards Subcommittee, and the Therapeutics and Technology Subcommittee, as well as serving on numerous work groups and task forces, including the Health Reform Task Force, the Solo and Small Group Task Force, and is currently serving as vice president of the AAN and chair of the AAN Board Planning Committee.

Stevens is a graduate of the Palatucci Advocacy Leadership Forum, has been a special advisor to the NINDS clinical research consortium, and is a past-president of the Indiana Neurological Society. He also served on the executive committee for the Lutheran Hospital of Indiana, and serves as chair of the board of directors for Physicians Health Plan of Indiana.

He has been the recipient of numerous awards, including the AAN Wartenberg Lecture, AHA Feinberg Award of Excellence in Clinical Stroke, the WSO Global Stroke Leadership Award, AHA Gold Heart Award, the NINDS Javits Award in neuroscience, and numerous named lectures.

He has been recognized annually as one the “Best Doctors in America,” and has been a recipient of the “Patients Choice Award” since 2008 as one of the outstanding physicians in the United States, and has received multi-year recognition as the “Top Doc” in neurology by the Fort Wayne Journal Gazette.

Sacco is a fellow of both the Stroke and Epidemiology Councils of the American Heart Association, a Fellow of the ANA, and an elected member of the American Association of Physicians.

He was the first neurologist to serve as the president of the American Heart Association from 2010 to 2011.

Vice President Ann H. Tilton, MD, FAAN

Sunday, April 23, 2017 • AANextra

Ann H. Tilton, MD, FAAN, is a professor of neurology and pediatrics and section chair of child neurology at Louisiana State Health Science Center in New Orleans, LA. She is director of the Rehabilitation Center at Children’s Hospital of New Orleans

and director of the Comprehensive Spasticity Program. Special interests include neurorehabilitation, neuromuscular disorders, and clinical applications and research in novel uses of botulinum toxin and intrathecal baclofen in the care of children and young adults with abnormal tone.

Tilton has been involved on the executive committee of the Professors of Child Neurology and active in the Ann H. Tilton, MD, FAAN national Child Neurology Society as a councilor, secretary/treasurer, and served as president of the organization. She is currently the president-elect of the Child Neurology Foundation. She is actively involved in the AAN Board of Directors, where she serves as the treasurer of the AAN Institute.

Introducing...

Residency education is one of her priorities and she served as a member and vice chair of the ACGME Neurology Residency Review Committee. She is just completing her role as the chair of the American Board of Psychiatry and Neurology.

Tilton’s interest in children with disabilities extends to the American Academy of Pediatrics where she served on the national Council for Children with Developmental Disabilities. Additionally, she is a certified member of the American Society of Neurorehabilitation and has been active on the executive committee.

Tilton has been board certified by the American Board of Pediatrics, the American Board of Psychiatry and Neurology with special qualifications in child neurology, and the American Board of Psychiatry and Neurology in clinical neurophysiology. She has published on numerous topics and has spoken nationally and internationally on child neurology, rehabilitation, and spasticity management.

Secretary Carlayne E. Jackson, MD, FAAN Carlayne E. Jackson, MD, FAAN, is currently professor of neurology and otolaryngology at the University of Texas Health Science Center San Antonio (UTHSCSA). She also serves as chief medical officer of UT Medicine and as assistant dean of ambulatory services for the School of Medicine.

Jackson is a graduate of Texas A&M University, where she received a bachelor’s of science degree in Carlayne E. Jackson, MD, FAAN chemical engineering. She obtained her medical degree at UTHSCSA, where she subsequently completed her neurology residency training and clinical neurophysiology fellowship. She has obtained board subspecialty certification in both clinical neurophysiology and neuromuscular medicine. She is a graduate of the Executive Leadership in Academic Medicine (ELAM) program sponsored by Drexel University College of Medicine.

Jackson serves as medical director for the South Texas ALSA Center of Excellence and the MDA ALS Research Center.

She is a member of the Western ALS Study Group, Northeast ALS Research Group, and the Muscle Study Group. She has

Join Neurology’s Global Conversation!

Connect with neurologists and neuroscience professionals in your area of interest.

Get started at AAN.com/Synapse

participated in over 60 multi-center clinical trials in the areas of ALS, muscular dystrophy, and myasthenia gravis and has published over 200 abstracts, journal articles, and book chapters.

Jackson has served the AAN as a member of the Science Committee, Meeting Management Committee, Leadership Development Committee, and the Board of Directors. She has been a member of the Continuum® editorial board since 2007.

She co-chaired the ALS Measurement Development Panel and co-authored the ALS Practice Parameters. She has actively participated on the Education Subcommittee and more recently on the Neuromuscular Topic Work Group. Jackson participated in the Palatucci Advocacy Leadership Forum in 2013, and has been a delegate to Neurology on the Hill. She has served as a mentor in the Emerging Leaders Forum for the past three years and the Diversity Leaders Program since its inception.

Treasurer Janis M. Miyasaki, MD, MEd, FRCPC, FAAN Janis M. Miyasaki, MD, MEd, FRCPC, FAAN, is a graduate of the University of Toronto Medical Faculty, neurology residency program, and a movement disorders fellowship. From 1994 to 1998, she was a community neurologist seeing general neurology patients and providing in-hospital care at a regional cancer and dialysis hospital.

In 1999, she joined the faculty of medicine at the University of

Toronto as full-time faculty, assuming the roles for various periods of director of education for neurology for four hospitals, ward chief, member of the Board of Trustees for the University Health Network, president of the Medical Staff Association, president of the Canadian Movement Disorders Group, deputy physician-in-chief at Toronto Western Hospital, and associate clinical director of the Movement Disorders Centre at Janis M. Miyasaki, MD, Toronto Western Hospital from 2001 MEd, FRCPC, FAAN to 2013. Her practice consisted of movement disorders, clinical trials, and the development of an interdisciplinary Palliative Care Program for Parkinson’s Disease and Related Disorders, the first of its kind in the world.

Since 2014, Miyasaki has been a member of the division of neurology at the University of Alberta and active in local and provincial initiatives in palliative care for neurologic patients.

Her AAN activities began in 2000 with writing a guideline on Parkinson’s disease. Since that time, she has worked on many AAN committees, including the Practice Committee, Technology and Therapeutics Subcommittee, Practice Improvement

Thank These AAN Leaders for Their Service Five neurology leaders are rotating off the AAN’s Board of Directors in April. Please join us in thanking them for their years of service to our members and their dedication to furthering the goals of the Academy and the profession of neurology.

Neil A. Busis, MD, FAAN 2011–2017 Board of Directors

Aaron E. Miller, MD, FAAN

Timothy A. Pedley, MD, FAAN

2009–2017 Board of Directors

2002–2017 Board of Directors

2013–2017 AAN Secretary

2011–2013 President Elect 2013–2015 President 2015–2017 Immediate Past President

Stefan M. Pulst, MD, FAAN

Lisa M. Shulman, MD, FAAN

2011–2017 Board of Directors

2007–2017 Board of Directors 2009–2013 AAN Secretary 2013–2017 AAN Treasurer

18

Sunday, April 23, 2017 • AANextra

Subcommittee, Patient Safety Subcommittee, and co-chaired the Technology and Therapeutics Subcommittee (now the Guideline Development Subcommittee) and Education Committee.

Between producing educational content, committees, working groups and meetings, she estimates since 2000 spending one day per month to a half-day per week on AAN work. It has been rewarding and energizing work.

Immediate Past President Terrence L. Cascino, MD, FAAN Terrence L. Cascino, MD, FAAN, is currently a professor of neurology, Mayo Clinic College of Medicine, at Mayo Clinic in Rochester. He has served as vice chair of the department of neurology and has been a leader in clinical practice at Mayo Clinic serving as the chair of the Clinical Practice Committee. He has served as Terrence L. Cascino, MD, FAAN the Juanita Kious Waugh Executive Dean for Education, Mayo Clinic, completing his tenure in October 2012. Cascino has chaired numerous committees in the American Academy of Neurology, including the Graduate Medical Education Committee and Education Committee, as well as having served as the AAN treasurer and AEI Board chair.

Directors Brenda Banwell, MD, FAAN* Sarah M. Benish, MD, FAAN Charlene Gamaldo, MD, FAAN* James N. Goldenberg, MD, FAAN*

Jonathan P. Hosey, MD, FAAN* Elaine C. Jones, MD, FAAN Brett M. Kissela, MD, MS, FAAN* John C. Morris, MD, FAAN Thomas R. Vidic, MD, FAAN

&

Neurosurgery

by

U.S. News & World Report,

2016-17. Our world-class specialists are commi ed to the discovery of new treatments for neurological conditions and hold faculty appointments at the Icahn School of Medicine at Mount Sinai, ranked among the nation’s top

Ex Officio (voting) Orly Avitzur, MD, MBA, FAAN Chair, Medical Economics and Management Committee

The Mount Sinai Hospital is ranked No.12 in Neurology

Robert A. Gross, MD, PhD, FAAN Editor-in-Chief of Neurology ®

Gregory D. Cascino, MD, FAAN Nicholas E. Johnson, MD Chair, Member Engagement Chair, Government Relations Committee Committee

Ex Officio (non-voting)

medical schools by U.S. News & World Report.

• Comprehensive Stroke Center • Bendheim Parkinson and Movement Disorders Center • Corinne Goldsmith Dickinson Center for Multiple Sclerosis • Center for Headache and Facial Pain • Neuromuscular Disease Division • Neurocritical Care • Neurovestibular and Balance Disorders

Catherine M. Rydell, CAE Executive Director/CEO

2017–2019 AAN Institute Board of Directors The following are additional members of the AAN Institute Board of Directors who do not serve on the AAN Board of Directors.

Officer

Ex Officio (voting)

Charles C. Flippen II, MD, FAAN Secretary-Treasurer

Natalia S. Rost, MD, MPH, FAAN, FAHA* Chair, Science Committee

• Center for Cognitive Health and Alzheimer’s Disease Research Center • Neuro-Infectious Diseases and NeuroAIDS Program • Epilepsy Center • Pediatric Neurology • Neuro-Oncology Program • Neuro-Ophthalmology Program

Heidi B. Schwarz, MD, FAAN Chair, Practice Committee A. Gordon Smith, MD, FAAN Chair, Education Committee *Denotes members new to the Board

1-800-MD-SINAI • mountsinai.org/msneuro

TR ANSFOR M THE TR E ATMENT OF PARKINSON’S DISEASE PSYCHOSIS NUPLAZID® (pimavanserin) IS THE FIRST AND ONLY FDA-approved therapy proven to reduce the symptoms of hallucinations and delusions without impacting motor function1

Change your outlook on Parkinson’s disease psychosis.

In vitro, NUPLAZID targets 5-HT2A and 5-HT2C receptors while demonstrating no appreciable binding affinity for dopamine, histamine, muscarinic, or adrenergic receptors. With a proven safety profile and no impact on motor function, once-daily NUPLAZID 34 mg can be prescribed with confidence.1

Visit booth #489 to experience the transformation with the Oculus virtual reality headset.

Indication NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Important Safety Information for NUPLAZID (pimavanserin) 17-mg Tablets WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.

QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination

with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

Adverse Reactions: The most common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

Drug Interactions: Strong CYP3A4 inhibitors (eg, ketoconazole) increase NUPLAZID concentrations.

Reduce the NUPLAZID dose by one-half.

Strong CYP3A4 inducers may reduce NUPLAZID exposure, only if the potential benefit justifies the potential risk to monitor for reduced efficacy. Increase in NUPLAZID dosage the mother and fetus. may be needed.

Pediatric Use: Safety and efficacy have not been established Renal Impairment: No dosage adjustment for NUPLAZID is in pediatric patients. needed in patients with mild to moderate renal impairment.

Dosage and Administration Use of NUPLAZID is not recommended in patients with Recommended dose: 34 mg per day, taken orally as two severe renal impairment.

17-mg tablets once daily, without titration.

Hepatic Impairment: Use of NUPLAZID is not You are encouraged to report negative side effects of recommended in patients with hepatic impairment. prescription drugs to the FDA. Visit www.fda.gov/medwatch NUPLAZID has not been evaluated in this patient or call 1-800-FDA-1088. You can also call ACADIA population.

Pharmaceuticals Inc. at 1-844-4ACADIA (1-844-422-2342).

Pregnancy: Use of NUPLAZID in pregnant women has not been evaluated and should therefore be used in pregnancy See Brief Summary of Prescribing Information on adjacent pages.

Reference: 1. NUPLAZIDŽ (pimavanserin) prescribing information, ACADIA. Š2017 ACADIA Pharmaceuticals Inc. All rights reserved. NU-0584 03/17.

T:6.875”

NUPLAZID™ (pimavanserin) tablets, for oral use.

Rx only Brief Summary: This information is not comprehensive.

Visit www.NUPLAZID.com to obtain the FDA-approved product labeling or call 1-844-422-2342.

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.

1 INDICATIONS AND USAGE NUPLAZID™ is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval.

6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling: • Increased Mortality in Elderly Patients with DementiaRelated Psychosis • QT Interval Prolongation Clinical Trial Experience The clinical trial database for NUPLAZID consists of over 1200 subjects and patients exposed to one or more doses of NUPLAZID. Adverse reactions that occurred in 6-week, placebo-controlled studies and that were reported at an incidence of ≥2%, and >placebo are presented in the following table.

2 DOSAGE AND ADMINISTRATION The recommended dose of NUPLAZID is 34 mg, taken orally as two 17-mg strength tablets once daily, without titration.

Adverse Reactions (≥2% and >Placebo)

• Coadministration with Strong CYP3A4 Inhibitors The recommended dose of NUPLAZID when coadministered with strong CYP3A4 inhibitors (e.g., ketoconazole) is 17 mg, taken orally as one tablet once daily.

• Coadministration with Strong CYP3A4 Inducers Monitor patients for reduced efficacy if NUPLAZID is used concomitantly with strong CYP3A4 inducers; an increase in NUPLAZID dosage may be needed.

5 WARNINGS AND PRECAUTIONS Increased Mortality in Elderly Patients with DementiaRelated Psychosis Antipsychotic drugs increase the all-cause risk of death in elderly patients with dementia-related psychosis. Analyses of 17 dementia-related psychosis placebo-controlled trials (modal duration of 10 weeks and largely in patients taking atypical antipsychotic drugs) revealed a risk of death in the drug-treated patients of between 1.6- to 1.7-times that in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in placebo-treated patients.

Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.

NUPLAZID is not approved for the treatment of patients with dementia related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.

QT Interval Prolongation NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin, moxifloxacin).

NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes

NUPL16CDLA0961_Brief_Summary_ASize_r3.indd 1

Placebo

N = 202

N = 231

Nausea

7%

4%

Peripheral edema

7%

2%

Confusional state

6%

3%

Hallucination

5%

3%

Constipation

4%

3%

Gait disturbance

2%

<1%

Hallucination includes visual, auditory, tactile, and somatic hallucinations

a

7 DRUG INTERACTIONS QT Interval Prolongation Concomitant use of drugs that prolong the QT interval may add to the QT effects of NUPLAZID and increase the risk of cardiac arrhythmia. Avoid the use of NUPLAZID in combination with other drugs known to prolong QT interval.

Strong CYP3A4 Inhibitors Concomitant use of NUPLAZID with a strong CYP3A4 inhibitor increases pimavanserin exposure. If NUPLAZID is used with a strong CYP3A4 inhibitor, reduce the dosage of NUPLAZID. Strong CYP3A4 Inducers Concomitant use of a strong CYP3A4 inducer may reduce pimavanserin exposure resulting in a potential decrease in efficacy. Patients should be monitored for reduced efficacy and an increase in dosage may be needed if NUPLAZID is used concomitantly with strong CYP3A4 inducers.

8 USE IN SPECIFIC POPULATIONS Pregnancy: There are no data on NUPLAZID use in pregnant women that would allow assessment of the drug-associated risk of major congenital malformations or miscarriage.

In animal reproduction studies, no adverse developmental effects were seen when pimavanserin was administered orally to rats or rabbits during the period of organogenesis at doses up to 10- or 12-times the maximum recommended human dose (MRHD) of 34 mg/day, respectively. Administration of pimavanserin to pregnant rats during pregnancy and lactation resulted in maternal toxicity and lower pup survival and body weight at doses which are 2-times the MRHD of 34 mg/day.

9/27/16 6:01 PM

T:9.75”

4 CONTRAINDICATIONS None.

NUPLAZID 34 mg

Preferred Term

T:6.875”

Lactation: There is no information regarding the presence of pimavanserin in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NUPLAZID and any potential adverse effects on the breastfed infant from NUPLAZID or from the underlying maternal condition.

Pediatric Use Safety and effectiveness of NUPLAZID have not been established in pediatric patients.

Geriatric Use No dose adjustment is required for elderly patients.

Parkinson’s disease is a disorder occurring primarily in individuals over 55 years of age. The mean age of patients enrolled in the 6-week clinical studies with NUPLAZID was 71 years, with 49% 65-75 years old and 31% >75 years old. In the pooled population of patients enrolled in 6-week, placebocontrolled studies (N=614), 27% had MMSE scores from 21 to 24 compared to 73% with scores ≥25. No clinically meaningful differences in safety or effectiveness were noted between these two groups.

17 PATIENT COUNSELING INFORMATION Concomitant Medication Advise patients to inform their healthcare providers if there are any changes to their current prescription or over-thecounter medications, since there is a potential for drug interactions.

CAUTION: Federal law prohibits dispensing without prescription.

NUPLAZID™ is a trademark of ACADIA Pharmaceuticals Inc. Distributed by: ACADIA Pharmaceuticals Inc. San Diego, CA 92130 NU-0381 09/16.

Renal Impairment No dosage adjustment for NUPLAZID is needed in patients with mild to moderate (CrCL ≥30 mL/min, Cockcroft-Gault) renal impairment. Use of NUPLAZID is not recommended in patients with severe renal impairment (CrCL <30 mL/min, Cockcroft-Gault). NUPLAZID has not been evaluated in this patient population.

T:9.75”

Hepatic Impairment Use of NUPLAZID is not recommended in patients with hepatic impairment. NUPLAZID has not been evaluated in this patient population.

9 DRUG ABUSE AND DEPENDENCE Controlled Substance NUPLAZID is not a controlled substance.

Abuse NUPLAZID has not been systematically studied in humans for its potential for abuse, tolerance, or physical dependence.

While short-term, placebo-controlled and long-term, openlabel clinical trials did not reveal increases in drug-seeking behavior, the limited experience from the clinical trials do not predict the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed.

10 OVERDOSAGE Human Experience The pre-marketing clinical trials involving NUPLAZID in approximately 1200 subjects and patients do not provide information regarding symptoms with overdose. In healthy subject studies, dose limiting nausea and vomiting were observed.

Management of Overdose There are no known specific antidotes for NUPLAZID. In managing overdose, cardiovascular monitoring should commence immediately and should include continuous ECG monitoring to detect possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine should not be used, as they have the potential for QT-prolonging effects that might be additive to those of NUPLAZID. Consider the long plasma half-life of pimavanserin (about 57 hours) and the possibility of multiple drug involvement.

NUPL16CDLA0961_Brief_Summary_ASize_r3.indd 2

9/27/16 6:01 PM

Education and Publications Station Experiential Learning Area Don’t Miss This Week’s Highlights

Are you up-to-date on the latest news, information, and education opportunities in neurology? Explore the AAN’s host of top-quality eLearning and publications offering the very latest science, education, news, and CME in neurology at the Education and Publications Station located on Northwest Lobby Level 1.

Highlights: 20% on-site discount to Continuum® —Stop by to subscribe or renew your subscription Continuum® Audio discount—$50 off one-year subscription Annual Meeting On Demand discount—Your last chance to purchase at the discounted rate!

AAN journals—Your one stop for all AAN journals, and a chance to learn how to submit to the newest Neurology ® subspecialty journals Online learning program demonstrations—Get a tour of the AAN’s suite of online learning programs—included free with your AAN membership!

Education presentations throughout the week—Check the AAN Annual Meeting App for a complete list of offerings but here are a few highlights: Oral Anticoagulation After Intracerebral Hemorrhage— Alesssanfro Biffi, MD How to Write MCQs: Making “Fair” and “Balanced” Mean Something—Douglas Gelb, MD, PhD, FAAN The Gamification of Neurology Education— Zachary London, MD, FAAN Using Continuum® for Resident Education— Steven L. Lewis, MD, FAAN How Early Can We Diagnose Alzheimer’s— Ronald C. Petersen, PhD, MD, FAAN

AAN Online MOC Exam Prep Course— Ralph Józefowicz, MD, FAAN Fulfill Your MOC Requirements and Lifelong Learning— A. Gordon Smith, MD, FAAN Amyloid Removal and Cognition in Alzheimer’s Disease— George Perry, PhD

Giveaways: Opportunities to win portable chargers and online access to Annual Meeting On Demand Free earbuds and a drawing for a set of Bose headphones— perfect for listening to Neurology ® Podcasts Stop in each day to learn more!

Get the Most Out of Your Week: Download the Annual Meeting Mobile App! Be sure and download the 2017 AAN Annual Meeting Mobile App to help you plan and get the most out of your week here in Boston. The handy app puts all the information you need to plan and customize your schedule on your smart phone or tablet: Search the full Annual Meeting program schedule Locate rooms View abstracts Access course syllabi and slides Submit course evaluations to earn CME Find out where all the fun social and networking events are taking place Get the latest meeting information and updates The 2017 Annual Meeting Mobile App is sponsored by Novartis Pharmaceuticals. Visit AAN.com/view/AMApp to download the app in iOS and Android formats, also available at the Apple Store or Google Play Store.

Learn About the Axon Registry at the Annual Meeting The AAN’s Axon Registry ® is your solution to fulfilling multiple regulatory requirements. Get a preview of the registry at the 2017 Annual Meeting in Boston.

The Axon Registry, a quality improvement and clinical data registry (QCDR), completed its pilot phase in 2016. Now, the Axon Registry is accepting practices to join in 2017. At the Annual Meeting, come talk with registry staff, sign up to participate in the Axon Registry, and see a registry user dashboard demonstration.

Lyell K. Jones, MD, FAAN

The Axon Registry booth, located in the Maximize Your Value: Improve Your Neurology Practice Experiential Learning Area on the main floor of the convention center, will have experts available for the entire meeting. Additionally, from April 22 through 25, a representative from registry vendor FIGMD will be available to answer technical questions and share information about the sign-up process. Stop by to

see demonstrations of the dashboard and learn how having registry data at your fingertips can be a valuable resource for your practice.

Boxed Lunch Menu Sunday, April 23

Southwest Grilled Chicken Wrap Sandwich Pepper jack cheese, spicy tomato spread, and chipotle aioli Turkey and Swiss Sandwich (GF) Honey-Dijon on GF Italian roll Grilled Italian Vegetable GF Sandwich (V, GF) Balsamic dressing and edamame spread Each lunch includes: black bean and roasted corn salad – grilled peppers and chipotle red wine vinaigrette, melon and feta cheese salad – mint syrup, cinnamon natilla – custard with cinnamon and vanilla (V, GF- coconut milk cinnamon natilla)

“With the release of the MACRA final rule in October 2016, now is the time to assess how you will fulfill Quality Payment Program requirements,” said Lyell K. Jones, MD, FAAN, chair of the Registry Committee. “The Axon Registry will help US neurologists satisfy the Quality component of MIPS, will attest to engaging with a QCDR for Advancing Care Information and for the Improvement Activity requirements. Also, the Axon Registry is approved by the American Board of Psychiatry and Neurology as an MOC Part IV PIP Clinical Module activity.”

If you’re looking for how Axon Registry participation will help your practice save time and be more efficient in handling reporting requirements and implement quality improvement initiatives, stop by the booth and get all your questions answered. Don’t miss this opportunity to learn how to successfully maximize the value of your practice.

V–vegan · GF–gluten free

Sunday, April 23, 2017 • AANextra

25

Tweets of the Day MiyaBernson-Leung

@MBernsonLeung Infographic: Coaches, Mentors, and Sponsors: Understanding the Differences http://www.catalyst.org/ knowledge/coaches-mentors-andsponsors-understanding-differences#.

WPvXCP8P30w.twitter … via @AddThis #AANAM #womeninleadership

D

avid Evans @davidevanstx

D

Thank you @tcascino1 for your leadership & unwavering dedication to advance neurology during your tenure as President of @AANMember #AANAM

avid Hale @NeuroHale

L

ila @lila_sheikhi

Neat to hear a perspective & ideas on maintaining professional digital profiles as an interactive platform at #AAN2017 #AANAM by @ohsuneuropic.twitter. com/dIQW7RP8cL

P

earce Korb, MD FAAN @drpearcekorb

Learning about work-life balance at #AANAM, crucial to prevent #burnout.

Check out the innovative HeadTalks schedule.pic.twitter.com/181EhJZOiP @drpearcekorb @AANMember First take home: more important than "balance" (mostly illusion) is work-life "well being", or a sense of control over work and life. #AANAM

@Teleneurology needs a bigger venue at next year's conference! #AANAM #Telemedicine

Novartis Neuroscience

Changing the practice of medicine At Novartis, we harness the innovation power of science to address some of society’s most challenging healthcare issues.

We are passionate about discovering new ways to improve and extend people’s lives.

© 2017 Novartis Pharma AG GMCC: GLNS/GILE/0193m eMED: M-GYA-1342959 Date of preparation: March 2017

Novartis Pharma AG CH-4056 Basel, Switzerland www.novartis.com

F O R A D U LT S W I T H TA R D I V E D Y S K I N E S I A ( T D ) , T H E F I R S T A N D O N LY I N D I C AT E D T R E AT M E N T

I N T R O D U C I N G

NO FDA-APPROVED TREATMENT HAS EXISTED—UNTIL NOW.

Discover a new treatment for your adult TD patients Visit us at booth #585 Important Information INDICATION & USAGE INGREZZA™ (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

IMPORTANT SAFETY INFORMATION WARNINGS & PRECAUTIONS Somnolence INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

QT Prolongation INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

ADVERSE REACTIONS The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and >placebo) include: anticholinergic effects, balance disorders/ falls, headache, akathisia, vomiting, nausea, and arthralgia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see the adjacent page for brief summary of Prescribing Information and visit www.INGREZZA.com for full Prescribing Information.

REFERENCE: INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc; 2017.

©2017 Neurocrine Biosciences, Inc. All Rights Reserved. CP-VBZ-US-0112 04/17

for oral use

Brief Summary: for full Prescribing Information and Patient Information, refer to package insert.

INDICATIONS AND USAGE

INGREZZA is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.

WARNINGS AND PRECAUTIONS

Somnolence INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA. QT Prolongation INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA concentrations may be higher and QT prolongation clinically significant. For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. For patients taking a strong CYP3A4 inhibitor, reduce the dose of INGREZZA to 40 mg once daily. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval.

For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

Endocrine Disorders: blood glucose increased General Disorders: weight increased Infectious Disorders: respiratory infections Neurologic Disorders: drooling, dyskinesia, extrapyramidal symptoms (non-akathisia) Psychiatric Disorders: anxiety, insomnia During controlled trials, there was a dose-related increase in prolactin. Additionally, there was a dose-related increase in alkaline phosphatase and bilirubin, suggesting a potential risk for cholestasis.

DRUG INTERACTIONS

Drugs Having Clinically Important Interactions with INGREZZA Table 2: Clinically Significant Drug Interactions with INGREZZA Monoamine Oxidase Inhibitors (MAOIs) Clinical Implication:

Prevention or Management: Examples: isocarboxazid, phenelzine, selegiline Strong CYP3A4 Inhibitors Clinical Implication:

ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling: • Somnolence • QT Prolongation Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Prevention or Management: Examples: Strong CYP2D6 Inhibitors

The safety of INGREZZA was evaluated in 3 placebo-controlled studies, each 6 weeks in duration (fixed dose, dose escalation, dose reduction), including 445 patients. Patients were 26 to 84 years of age with moderate to severe tardive dyskinesia and had concurrent diagnoses of mood disorder (27%) or schizophrenia/schizoaffective disorder (72%). The mean age was 56 years. Patients were 57% Caucasian, 39% African-American, and 4% other. With respect to ethnicity, 28% were Hispanic or Latino. All subjects continued previous stable regimens of antipsychotics; 85% and 27% of subjects, respectively, were taking atypical and typical antipsychotic medications at study entry.

Adverse Reactions Leading to Discontinuation of Treatment A total of 3% of INGREZZA treated patients and 2% of placebo-treated patients discontinued because of adverse reactions.

Common Adverse Reactions Adverse reactions that occurred in the 3 placebo-controlled studies at an incidence of ≥2% and greater than placebo are presented in Table 1.

Table 1: Adverse Reactions in 3 Placebo-Controlled Studies of 6-week Treatment Duration Reported at ≥2% and >Placebo INGREZZA (n=262) (%)

Placebo (n=183) (%)

Concomitant use of INGREZZA with strong CYP2D6 inhibitors may increase the exposure (Cmax and AUC) to valbenazine’s active metabolite compared with the use of INGREZZA alone.

Increased exposure of active metabolite may increase the risk of exposure-related adverse reactions.

Prevention or Management:

Consider reducing INGREZZA dose based on tolerability when INGREZZA is coadministered with a strong CYP2D6 inhibitor.

Examples:

paroxetine, fluoxetine, quinidine

10.9%

4.2%

Anticholinergic effects (dry mouth, constipation, disturbance in attention, vision blurred, urinary retention)

5.4%

4.9%

Balance disorders/fall (fall, gait disturbance, dizziness, balance disorder)

4.1%

2.2%

Headache Akathisia (akathisia, restlessness)

3.4% 2.7%

2.7% 0.5%

2.6% 2.3%

0.6% 2.1%

2.3%

0.5%

Strong CYP3A4 Inducers Clinical Implication:

Prevention or Management: Examples: Digoxin

General Disorders Somnolence (somnolence, fatigue, sedation) Nervous System Disorders 1

Gastrointestinal Disorders Vomiting Nausea Musculoskeletal Disorders Arthralgia 1

Within each adverse reaction category, the observed adverse reactions are listed in order of decreasing frequency.

Other Adverse Reactions Observed During the Premarketing Evaluation of INGREZZA Other adverse reactions of ≥1% incidence and greater than placebo are shown below.

The following list does not include adverse reactions: 1) already listed in previous tables or elsewhere in the labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have clinically significant implications, or 5) which occurred at a rate equal to or less than placebo.

Concomitant use of INGREZZA with strong CYP3A4 inhibitors increased the exposure (Cmax and AUC) to valbenazine and its active metabolite compared with the use of INGREZZA alone. Increased exposure of valbenazine and its active metabolite may increase the risk of exposure-related adverse reactions.

Reduce INGREZZA dose when INGREZZA is coadministered with a strong CYP3A4 inhibitor. itraconazole, ketoconazole, clarithromycin

Clinical Implication:

Variable and Fixed Dose Placebo-Controlled Trial Experience

Adverse Reaction1

Concomitant use of INGREZZA with MAOIs may increase the concentration of monoamine neurotransmitters in synapses, potentially leading to increased risk of adverse reactions such as serotonin syndrome, or attenuated treatment effect of INGREZZA. Avoid concomitant use of INGREZZA with MAOIs.

Concomitant use of INGREZZA with a strong CYP3A4 inducer decreased the exposure of valbenazine and its active metabolite compared to the use of INGREZZA alone. Reduced exposure of valbenazine and its active metabolite may reduce efficacy.

Concomitant use of strong CYP3A4 inducers with INGREZZA is not recommended. rifampin, carbamazepine, phenytoin, St. John’s wort1

Clinical Implication:

Concomitant use of INGREZZA with digoxin increased digoxin levels because of inhibition of intestinal P-glycoprotein (P-gp).

Prevention or Management:

Digoxin concentrations should be monitored when co-administering INGREZZA with digoxin. Increased digoxin exposure may increase the risk of exposure related adverse reactions. Dosage adjustment of digoxin may be necessary.

The induction potency of St. John’s wort may vary widely based on preparation.

Drugs Having No Clinically Important Interactions with INGREZZA Dosage adjustment for INGREZZA is not necessary when used in combination with substrates of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, or CYP3A4/5 based on in vitro study results.

OVERDOSAGE

Human Experience The pre-marketing clinical trials involving INGREZZA in approximately 850 subjects do not provide information regarding symptoms with overdose.

Management of Overdosage No specific antidotes for INGREZZA are known. In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement. If an overdose occurs, consult a Certified Poison Control Center (1-800-222-1222 or www.poison.org).

For further information on INGREZZA, call 84-INGREZZA (844-647-3992).

Distributed by: Neurocrine Biosciences, Inc. San Diego, CA 92130 INGREZZA is a trademark of Neurocrine Biosciences, Inc. CP-VBZ-US-0203 04/17

Luncheon Brings Together Past, Present, and Future Presidents Past AAN presidents on-site in Boston came together for their annual luncheon on Saturday. They were joined by President Terrence L. Cascino, MD, FAAN, and President Elect Ralph L. Sacco, MD, MS, FAHA, FAAN. They saluted Cascino for his leadership over the past two years and shared their observations on a range of topics affecting the neurology profession.

The group paused to honor the memory of Lewis P. Rowland, MD, FAAN, who served as president from 1989–1991. Rowland had planned on attending the meeting but passed away on March 16 at the age of 91.

FAAN (2003–2005); Thomas R. Swift, MD, FAAN (2005–2007); Stephen M. Sergay, MB BCh, FAAN (2007–2009); Robert C. Griggs, MD, FAAN (2009–2011); Bruce Sigsbee, MD, FAAN (2011–2013); and Timothy A. Pedley, MD, FAAN (2013–2015).

Steven P. Ringel, MD, FAAN (1997–1999) arrived in Boston after the luncheon. Nelson G. Richards, MD, FAAN, (1983–1985) was unable to attend the Annual Meeting.

In attendance were: Roger N. Rosenberg, MD, FAAN (1991– 1993); Francis I. Kittredge, Jr., MD, JD, FAAN (1999–2001); Stanley Fahn, MD, FAAN (2001–2003); Sandra F. Olson, MD, Top: From left, Bruce Sigbee, MD, FAAN, Timothy A. Pedley, MD, FAAN, and his wife, Barbara S. Koppel, MD, FAAN. Stanley Fahn, MD, FAAN, left, conferred with President Elect Ralph L. Sacco, MD, MS, FAHA, FAAN. Far Right: Stephen M. Sergay, MB BCh, FAAN

In Memoriam: Lewis P. (Bud) Rowland Neurology legend Lewis P. (Bud) Rowland, MD, FAAN, passed away on March 16, 2017, at age 91. Rowland served as AAN president from 1989 to 1991, and was editor-in-chief of Neurology ® from 1977 to 1986. He was the founding editor-in-chief of Neurology Today ® from 2001 through 2009, and was president of the AAN’s Education and Research Foundation (now the American Brain Foundation) from 1996 to 1999.

“The AAN and our profession has lost a true giant in neurology,” said President Elect Ralph L. Sacco, MD, MS, FAHA, FAAN. “Bud was a leader, advocate, teacher, mentor, and friend who personally touched so many of us. He inspired us to always do more for our patients and the field of neurology. We will miss his warmth, wit, and encouraging words,

but he lives in our fond memories forever.”

Rowland was a professor in neurology at Columbia University from 1957 to 1967, when he began a six-year stint as professor and chair of neurology at the University of Pennsylvania. He then returned to Columbia to chair the neurology department from 1973 to 1998. He was past president of the American Neurological Association, the New York Neurological Society, and the Association of University Professors of Neurology, The Parkinson’s Disease Foundation, and member of numerous NIH committees. His awards and honors, too numerous to mention in their entirety, include the AAN’s Presidential Award in 1993.

Steven P. Ringel, MD, FAAN, president at the time Neurology Today was launched, said, “It was an easy choice to select Bud Rowland as the first editor of Neurology Today.

His stature, leadership, and breadth of knowledge guaranteed success. My admiration for him steadily grew in the nine years we worked together on the publication.”

Rowland received his BA and MD degrees from Yale University and completed his residency under H. Houston Merritt at the New York Neurological Institute. He was a clinical associate at NINDS, focusing on neuromuscular disease, and taught neurology at Georgetown University.

Sunday, April 23, 2017 • AANextra

29

Choosing the Right Practice Setting

continued from page 7

Solo practice offers immediate rewards for efficiency and solo physicians rise or fall based on their own merit. In today’s complicated health care world, this practice setting has some disadvantages. Solo physicians must be excellent businesspersons and clinicians. Administrative tasks demand time, restricting clinical time available for quality patient care.

Developing a patient base alone takes more time, and the solo practitioner takes full financial responsibility and personal risk for actions and decisions.

Take time to think about your personal practice style and desired balance of risk versus reward in order to find the practice setting that is right for you.

Daily Reminders

Employment has recently grown in popularity, especially with the ambiguity surrounding health care reform legislation. There are many options for employment, including government, corporate, and industry. Employed physicians have the security of a guaranteed paycheck and employee benefits without financial risk. They bear no start up costs and walk into a structured work environment with practice management support. Free of business worries, the employed physician can focus on patient care during regularly set work hours and then retreat home at the end of the day. Contrary to private practice settings, however, there is seldom any ownership potential and with multiple layers of management and bureaucracy, physicians have little control over staff or workload. Additionally, the practitioner’s future is closely tied to the organization’s success.

Academia is also an available option. Academia offers prestige, the opportunity to give specialized care, and the challenge of unique cases. Combining research and educational time with clinical opportunities gives variety in daily activities. On the downside, compensation is often a base salary with limited income growth opportunity and may be linked to grant funding.

Additionally, time for direct patient care is limited by other responsibilities, such as teaching or serving on committees.

Education Program Syllabi and Slides Available Online Only Education Program syllabi and slides are available online only at AAN.com/view/syllabi or through the Annual Meeting Mobile App at AAN.com/view/app.

May 8 Is Deadline to Submit Online Evaluations for Annual Meeting CME Complete your evaluations to get your CME hours by using the Annual Meeting Mobile App at AAN.com/view/ app or by visiting AAN.com/view/CME. CME requests may be made until May 8, 2017.

Save 10 Percent Shopping Online at The AAN Store®!

B:8.5”

This year, Annual Meeting attendees can receive 10 percent off online orders placed by April 28 at AAN.com/ AANStore. Go online, shop, and use Promo Code AM10 at checkout for your Annual Meeting discount.

T:8.25” S:7.25”

INDUSTRY THERAPEUTIC UPDATE FROM ELI LILLY Advance your understanding of Amyvid and join our upcoming live reader training program—now with updated content SPEAKERS

LOCATION

Dr. Paul Schulz Dr. James O’Donnell Imaging Specialist

Seaport Hotel & World Trade Center, Plaza Ballroom, 1 Seaport Lane, Boston, MA 02210

DATE/TIME

REGISTER AT

Dementia Specialist

April 26, 2017 at 7:00 PM No CME will be given.

It is not an AAN endorsed event or a part of the AAN official programming. ©Lilly USA, LLC 2017. All rights reserved. PP-AM-US-0167 03/2017 Amyvid™ is a trademark of Eli Lilly and Company.

Booth 591

VISIT BOOTH 591 FOR MORE DETAILS.

NOW APPROVED

SEE WHAT WE’RE DOING NOW AT

BOOTH 501 B:4.6875”

S:3.4375”

T:4.4375”

© 2017 Genentech USA, Inc. All rights reserved. Printed in the USA. OCR/030117/0027 03/17

Complete Neurology Survey to Get This Free ‘Essential Tool’ Active US AAN members who complete the Academy’s fifth annual Neurology Compensation and Productivity Survey can gain free access to the Neurology Compensation and Productivity Report and results dashboard (a $600 value). The survey is open until May 6, and the report will be available in July.

The AAN’s Neurology Compensation and Productivity Report is the only survey and report dedicated solely to neurology. The survey results are kept confidential and secure and are reported only in aggregate. By completing the survey and accessing the free report and results dashboard, members will be able to benchmark their compensation and productivity against national benchmarks to make smart business decisions. The report and customizable dashboard empowers members to: Compare and customize your individual practice-related data with your colleagues at local and national levels Determine if you are being compensated fairly relative to your peers Use the data in demonstrating your value to payers and delivering quality patient care Discover fair market value based on your subspecialty, region, and practice type Create charts and graphs and download them right to your desktop Assess patient and practice management principles and implement efficiencies that ultimately can help improve the quality of patient care “The AAN’s Neurology Compensation and Productivity Report is an essential tool for our practice,” said David A. Evans, MBA, chief operating officer of Texas Neurology in Dallas and chair of

THE AAN ANNUAL MEETING

DISCOVER ADVANCED NEUROMUSCULAR TESTING Learn more about panel testing for neuromuscular disorders—including Pompe disease. A complimentary program is available for targeted DNA analysis of up to

the AAN’s Practice Management & Technology Subcommittee.

“By having comparative data, we have been able to identify variances in several areas to include compensation, call pay, benefits, and RVUs. I also use it to analyze the ratios between metrics, such as compensation-to-RVUs and call-pay-to-number of hospital beds. When I filter using varying criteria on the report’s online dashboard, I am always finding actionable data points.”

Free 2016 Summary Opens Window to Data You Can Use Want an idea of what is included in the report? Visit the Maximize Your Value Experiential Learning Area or go online at AAN.com/ view/benchmark to receive a complimentary executive summary from the 2016 Neurology Compensation and Productivity Report containing valuable neurology benchmark statistics, such as the US median annual compensation by practice setting, median work RVU by practice setting, and much more.

Nearly 1,400 members completed the survey in 2016, double the number of members who completed it in 2013.

More than a third of the participants in the past three years have completed the survey two or more times during that period. Repeating the survey

Muscle biopsy Acid a-glucosidase Various blood tests Electrocardiograms Nerve conduction tests Pulmonary function tests

31 separate conditions.1

Reflex testing

Testing early can help impact a 13-year diagnostic delay for Pompe disease.* 2-4

X-rays

Visit Sanofi Genzyme at Booth #729 to learn more.

Magnetic resonance imaging Sleep studies Targeted DNA analysis1

* Based on the median diagnostic gap.

www.pompe.com ©2017 Genzyme Corporation. All rights reserved. GZUS.PD.15.07.1915(1)

References: 1. Limb Girdle Muscular Dystrophy Consortium. http://www.lgmd-diagnosis.org/physician-portal. Accessed March 30, 2015. 2. Toscano A, Montagnese F, Musumeci O. Early is better? A new algorithm for early diagnosis in late-onset Pompe disease (LOPD). Acta Myol. 2013;32(2):78-81. 3. Kishnani PS, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J; Pompe Registry Boards of Advisors. Timing of diagnosis of patients with Pompe disease: data from the Pompe Registry. Am J Med Genet A. 2013;161A(10):2431-2443. 4. Winkel LP, Hagemans ML, van Doorn PA, et al. The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol. 2005;252(8):875-884.

Where Is can help members measure the results of changes they have made in their practices due to the data produced by the surveys.

For more information or to begin the survey, visit AAN.com/view/benchmark or contact benchmark@aan.com.

?

This year, the place to find The AAN Store® is online only at AAN.com/AANStore.

And Annual Meeting attendees can receive 10 percent off online orders placed

by April 28. For AAN members, this is an EXTRA 10 percent off beyond their usual member discount!

How do you get this 10-percent discount?

It’s as easy as this:

Visit Maximize Your Value: Improve Your Neurology Practice in the Experiential Learning Area Are you employing the best strategies for ensuring the success of your practice? Discover the best business practices for neurology and leave with readily implementable strategies on how to grow and sustain your practice.

Get your most pressing questions answered at the daily “Ask the Expert” booth and learn about a variety of topics from quality improvement to demonstrating your value as a neurologist at the presentation stage.

Go to AAN.com/AANStore Shop for high-quality neurology educational and clinical tools Then use discount Promo Code AM10 at checkout That’s all you need to do to order highquality neurology tools and resources and have them shipped directly to you, avoiding hassles with customs declarations or shipping from the Annual Meeting. Plus, you save 10 percent—and much more if you are an AAN member.

Shop today at AAN.com/AANStore and save!

Visit our booth for information about a treatment option for a rare disease Learn more about KEVEYIS® and Strongbridge CareConnection patient support at Booth 889.

900 Northbrook Drive, Suite 200 Trevose, PA 19053 United States www.KEVEYIS.com www.strongbridgebio.com © 2017 Strongbridge Biopharma plc STRONGBRIDGE BIOPHARMA™ is a trademark of Strongbridge Biopharma plc.

KEVEYIS® is a registered trademark licensed exclusively in the US to Strongbridge Biopharma plc.

KEV026-05 03/2017

There’s an important question being asked at the 2017 AAN Annual Meeting

UNCOVERING THE UNMET NEEDS IN MULTIPLE SCLEROSIS

Celgene invites you to share your thoughts about the unmet needs in the treatment of MS at BOOTH #779.

To participate: STOP by the Celgene booth • SCAN your badge • SUBMIT a word or phrase that best states a current unmet need in MS •

In addition to an initial $10,000 donation, for every visitor who contributes an unmet need to the discussion, Celgene will donate to the Multiple Sclerosis Association of America (MSAA).

Your voice matters. Come tell us WHAT’S MS’ing. © 2017 Celgene Corporation All rights reserved. 04/17 USII-CELG170023

This Morning’s Presidential Plenary Session to Showcase Most Significant Findings in Neurology continued from cover Sidney Carter Award in Child Neurology J. Helen Cross, PhD UCL-Institute of Child Health, London, United Kingdom Improving Outcomes in Childhood Epilepsy

Moderator Natalia Sana Rost, MD, FAAN Vice Chair, AAN Science Committee

Natalia Sana Rost, MD, FAAN

J. Helen Cross, PhD

Presidential Lecture Terrence L. Cascino, MD, FAAN Mayo Clinic, Rochester, MN Burnout, Wellness, and the Future of Our Profession

Robert Wartenberg Lecture Ronald C. Petersen, PhD, MD, FAAN Mayo Clinic, Rochester, MN How Early Can We Diagnose Alzheimer’s Disease?

Terrence L. Cascino, MD, FAAN

B:11.125” T:10.875” S:9.62”

H. Houston Merritt Lecture Nancy J. Newman, MD, FAAN Emory University School of Medicine, Atlanta, GA Ophthalmoscopy in the 21st Century

Nancy J. Newman, MD, FAAN

Ronald C. Petersen, PhD, MD, FAAN

Tomorrow’s Contemporary Clinical Issues Plenary Session Set to Highlight Issues Most Critical to Practicing Neurologists

Three abstract presenters and three invited speakers will come together at 9:15 a.m. Monday morning in Exhibit Hall A to highlight issues most critical to practicing neurologists, including abstracts related to new therapeutic developments, clinical applications of basic and translational research, and innovative technical developments.

Commentary and discussion follow each presentation.

Set Yourself Apart Get the recognition you deserve. Add the Fellow of the AAN (FAAN) designation to your already impressive credentials.

Learn how at AAN.com/view/FAAN.

What Are P What are you looking forward to the most besides your presentation?

I’ve been here since this morning and so far I’ve seen a lot of diversity. I got to sit in on a talk about concussions this morning and just left a session on advocacy. I'm here to take in a lot of different topics and do some networking as well.

Erin Balcom Student Member Toronto, ON

What are you looking forward to the most during the coming week?

A lot of the educational conferences for learning new ways to teach residents. Some of the advances in technology that can be hard to keep upto-date with. We’re doing a bunch of initiatives at NYU with integrated medical education and so we have a program where residents have iPhones and iPads and so we need to stay abreast of the current technological developments in medicine in general but also for neurology education.

36

Sunday, April 23, 2017 • AANextra

Aaron Nelson, MD Neurologist Member New York, NY

People Saying?

Are you looking forward to doing some networking while you’re here?

Well, I'm definitely going to be part of the new Section on Neurohealth and Integrative Neurology and attending the meetings on neurohealth and integrative neurology as well as the Stroke Section. So I will be networking with those individuals and trying to see what kind of progress we can develop for the future as part of the sections.

Ravinder Singh, MD Neurologist Member Beverly Hills, CA

What are you looking forward to learning when you're here?

What are you looking forward to the most this week?

A combination of attending courses and meeting colleagues. I enjoy meeting up with long-term colleagues that are scattered all over the country that I’ve either trained with or are mentors that I get to see here and interact with.

First of all, general neurology updates on treatment of different neurological diseases. And focusing on some diseases like neuromuscular disorders, that is my specialty, like myasthenia, inherited neuropathy, and ALS. Imen Kacem, MD International Scholarship Recipient La Manouba, Tunisia

Are you looking forward to networking with other neurologists?

Yes, of course. Here in the US there is a collaboration with Tunisia and some other countries and we hope we will have another collaboration.

What advice would you give a first-time attendee?

Don’t be overwhelmed.

Enjoy it. Find what you’re interested in and learn as much as you can.

Mircea Morariu, MD Neurologist Member Delray Beach, FL

What are you looking forward to the most this week?

First, I am interacting with other neurologists; we are doing the work here in the advanced countries because we are belonging to the second-world nations. Second thing: I compare myself with others—how we are performing there. Third: What is the latest? What can we achieve with our patients? That is my motive to come to this conference.

Kartikeya Sharma, MBBS Nonmember Allahabad, India

Sunday, April 23, 2017 • AANextra

37

Meet the Neurology Resident & Fellow Section Editors and Team Members Want to know more about the Resident & Fellow section in Neurology ® ? Would you like to learn about how you can get involved? Take advantage of these great opportunities to meet the editors and other team members while you are here at the Boston Convention & Exhibition Center (BCEC).

Being a Great Chief Resident Sunday, April 23, 3:00 p.m.–3:30 p.m.

Roy E. Strowd III, MD Track Talk Research in Residency: How to Choose the Right Project Monday, April 24, 11:00 a.m.–11:45 a.m.

Roy E. Strowd III, MD Track Talk

Faculty and Trainee Reception

Monday, April 24, 6:00 p.m.–9:00 p.m.

BCEC Ballroom East/West Register to win an iPad mini!

Using the R&F Section of Neurology for Your Residents and Residency Monday, April 24, 3:00 p.m.–3:30 p.m.

Roy E. Strowd III, MD, and John J. Millichap, MD Track Talk Everything You Wanted to Know About the R&F Section of Neurology Tuesday, April 25, 3:00 p.m.–3:30 p.m.

Roy E. Strowd III, MD, and John J. Millichap, MD Track Talk

Education and Publication Station Roy E. Strowd III, MD

Experiential Learning Area BCEC Level 1 NW Lobby

John J. Millichap, MD

Navigating Your Career

Experiential Learning Area BCEC Level 1 NE Lobby Writing and Reviewing for the R&F Section of Neurology Sunday, April 23, 1:00 p.m.–1:30 p.m.

Roy E. Strowd III, MD, and John J. Millichap, MD Track Talk

B:8.5”

Tips for Successful Submission to Neurology Resident & Fellow Section Monday, April 24, 4:00 p.m.–5:00 p.m.

Roy E. Strowd III, MD, and John J. Millichap, MD Stage

T:8.25” S:7.25”

FIGHT BACK EARLY WITH GILENYA® (fingolimod) 4/23–4/26 | Boston, MA

KRISTIN

“I got the tears out of my system and got ready for my fight.”

STACEY “My story is a comeback story.”

People who have experience with GILENYA. They have been compensated for their time.

GILENYA is a registered trademark of Novartis AG.

Step inside the ring at booth 547

Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080

JAMES “You can keep going after your diagnosis.”

Hear from real GILENYA patients in the Patient Video Center Explore the MOA module, and watch the immersive MOA video See “The Story of GILENYA: Inspired by Nature, Refined by Science”

© 2017 Novartis

3/17

T-GYA- 1342233

TAKE A LOOK INSIDE

VISIT

BOOTH 591 To learn more, including details on our live reader training.

B:4.6875”

S:3.4375”

T:4.4375”

©Lilly USA, LLC 2017. All rights reserved. PP-AM-US-0166 03/2017. Amyvid™ is a trademark of Eli Lilly and Company.

VISIT US IN BOOTH #244

©2017 Biogen. All rights reserved. 03/17 TEC-US-2005